Barry I Freedman1, Amy L Kistler2, Peter Skewes-Cox2, Don Ganem2, Mitzie Spainhour1, Jolyn Turner1, Jasmin Divers3, Carl D Langefeld3, Mariana Murea1, Pamela J Hicks4, Ashok K Hemal5, James A Snipes1, Lihong Zhao2, Johanna R Abend2, Douglas S Lyles4, Lijun Ma1, Karl L Skorecki6. 1. Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA. 2. Infectious Diseases Area, Novartis Institutes for Biomedical Research, Emeryville, CA, USA. 3. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA. 4. Department of Biochemistry, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA. 5. Department of Urology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA. 6. Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology and Department of Nephrology, Rambam Health Care Campus, Haifa, Israel.
Abstract
Background: Viral infections can trigger chronic kidney disease (CKD) and the urine virome may inform risk. The Natural History of APOL1-Associated Nephropathy Study (NHAANS) reported that urine JC polyomavirus (JCPyV) associated with a lower risk of APOL1-associated nephropathy in African Americans. Herein, association was assessed between urine JCPyV with CKD in African Americans independent from the APOL1 genotype. Methods: Quantitative polymerase chain reaction was performed for urinary detection of JCPyV and BK polyoma virus (BKPyV) in 200 newly recruited nondiabetic African Americans. A combined analysis was performed in these individuals plus 300 NHAANS participants. Results: In the 200 new participants, urine JCPyV was present in 8.8% of CKD cases and 45.8% of nonnephropathy controls (P = 3.0 × 10-8). In those with APOL1 renal-risk genotypes, JCPyV was detected in 5.1% of cases and 40.0% of controls (P = 0.0002). In those lacking APOL1 renal-risk genotypes, JCPyV was detected in 12.2% of cases and 48.8% of controls (P = 8.5 × 10-5). BKPyV was detected in 1.3% of cases and 0.8% of controls (P = 0.77). In a combined analysis with 300 NHAANS participants (n = 500), individuals with urine JCPyV had a 63% lower risk of CKD compared with those without urine JCPyV (odds ratio 0.37; P = 4.6 × 10-6). RNA fluorescence in situ hybridization confirmed the presence of JCPyV genomic DNA and JCPyV messenger RNA (mRNA) in nondiseased kidney. Conclusions: Inverse relationships exist between JCPyV viruria and non-diabetic CKD. Future studies should determine whether renal inflammation associated with CKD is less permissive for JCPyV reactivation/replication or whether JCPyV is a marker of reduced host immune responsiveness that diminishes immune pathologic contributions to CKD.
Background: Viral infections can trigger chronic kidney disease (CKD) and the urine virome may inform risk. The Natural History of APOL1-Associated Nephropathy Study (NHAANS) reported that urine JC polyomavirus (JCPyV) associated with a lower risk of APOL1-associated nephropathy in African Americans. Herein, association was assessed between urine JCPyV with CKD in African Americans independent from the APOL1 genotype. Methods: Quantitative polymerase chain reaction was performed for urinary detection of JCPyV and BK polyoma virus (BKPyV) in 200 newly recruited nondiabetic African Americans. A combined analysis was performed in these individuals plus 300 NHAANS participants. Results: In the 200 new participants, urine JCPyV was present in 8.8% of CKD cases and 45.8% of nonnephropathy controls (P = 3.0 × 10-8). In those with APOL1 renal-risk genotypes, JCPyV was detected in 5.1% of cases and 40.0% of controls (P = 0.0002). In those lacking APOL1 renal-risk genotypes, JCPyV was detected in 12.2% of cases and 48.8% of controls (P = 8.5 × 10-5). BKPyV was detected in 1.3% of cases and 0.8% of controls (P = 0.77). In a combined analysis with 300 NHAANS participants (n = 500), individuals with urine JCPyV had a 63% lower risk of CKD compared with those without urine JCPyV (odds ratio 0.37; P = 4.6 × 10-6). RNA fluorescence in situ hybridization confirmed the presence of JCPyV genomic DNA and JCPyV messenger RNA (mRNA) in nondiseased kidney. Conclusions: Inverse relationships exist between JCPyV viruria and non-diabetic CKD. Future studies should determine whether renal inflammation associated with CKD is less permissive for JCPyV reactivation/replication or whether JCPyV is a marker of reduced host immune responsiveness that diminishes immune pathologic contributions to CKD.
Authors: Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Allison E Ashley-Koch; Emmanuel C Okocha; Melanie E Garrett; Karen Soldano; Laura M De Castro; Jude C Jonassaint; Eugene P Orringer; James R Eckman; Marilyn J Telen Journal: Br J Haematol Date: 2011-09-13 Impact factor: 6.998
Authors: Ana Bárcena-Panero; Marijke Van Ghelue; Mahmud Tareq Hassan Khan; Juan E Echevarría; Giovanni Fedele; Ugo Moens Journal: J Cell Physiol Date: 2012-01 Impact factor: 6.384
Authors: Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Jasmin Divers; Marina Núñez; Kevin P High; Mariana Murea; Michael V Rocco; Lijun Ma; Donald W Bowden; Pamela J Hicks; Mitzie Spainhour; David A Ornelles; Steven B Kleiboeker; Kara Duncan; Carl D Langefeld; Jolyn Turner; Barry I Freedman Journal: Kidney Int Date: 2013-05-15 Impact factor: 10.612
Authors: Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman Journal: J Am Soc Nephrol Date: 2014-07-10 Impact factor: 10.121
Authors: Etty Kruzel-Davila; Jasmin Divers; Gregory B Russell; Zipi Kra-Oz; Moran Szwarcwort Cohen; Carl D Langefeld; Lijun Ma; Douglas S Lyles; Pamela J Hicks; Karl L Skorecki; Barry I Freedman Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Sara Querido; Carolina Ormonde; Teresa Adragão; Inês Costa; Maria Ana Pessanha; Perpétua Gomes; André Weigert Journal: Int J Nephrol Date: 2021-08-19
Authors: Pepe M Ekulu; Agathe B Nkoy; Oyindamola C Adebayo; Orly K Kazadi; Michel N Aloni; Fanny O Arcolino; Rene M Ngiyulu; Jean-Lambert E Gini; François B Lepira; Lamberthus P Van den Heuvel; Elena N Levtchenko Journal: Pediatr Nephrol Date: 2020-04-06 Impact factor: 3.714
Authors: June Fabian; Jaya A George; Sean D Currin; Mwawi S Gondwe; Nokthula B Mayindi; Shingirai Chipungu; Bongekile L Khoza; Stephen Tollman Journal: BMC Nephrol Date: 2021-03-20 Impact factor: 2.388
Authors: Jasmin Divers; Carl D Langefeld; Douglas S Lyles; Lijun Ma; Barry I Freedman Journal: Curr Opin Nephrol Hypertens Date: 2019-01 Impact factor: 3.416